![](https://i0.wp.com/shacklemedia.com/wp-content/uploads/2023/02/pfizer-is-moving-beyond-covid-why-its-stock-is-a-buy.jpg?w=640&ssl=1)
Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leading treatment, Paxlovid.
The world, however, has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the price. The sales of its two Covid blockbusters may decline over 60% in 2023, after generating a combined $57 billion in revenue during 2022. And there is considerable uncertainty about demand for both in the coming years.
Source: finance.yahoo.com
Related posts:
ChatGPT Will Disrupt Many Jobs. These Are the Most at Risk.
Elon Musk lights blaze of speculation over gonzo share buyback a week before Tesla Q3 earnings
Bond vigilantes are 'saddling up.' Here's how concerned investors might take action over the balloon...
Where to Put Your Money During a Banking Crisis
1 Top Cryptocurrency to Buy Before It Soars 3,400%, According to Cathie Wood's Ark Invest